Dexilant
Total Payments
$565,871
Transactions
22,379
Doctors
7,557
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $21,203 | 9 | 1 |
| 2023 | $5,000 | 1 | 1 |
| 2019 | $30,275 | 2,113 | 1,328 |
| 2018 | $142,216 | 9,679 | 3,789 |
| 2017 | $367,177 | 10,577 | 5,159 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $258,023 | 93 | 45.6% |
| Food and Beverage | $245,334 | 22,039 | 43.4% |
| Travel and Lodging | $32,574 | 10 | 5.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,752 | 5 | 3.5% |
| Honoraria | $5,000 | 1 | 0.9% |
| Consulting Fee | $3,092 | 3 | 0.5% |
| Education | $2,096 | 228 | 0.4% |
Payments by Type
General
$307,848
22,286 transactions
Research
$258,023
93 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety and effecxtiveness of TAK-390MR in 1-11yr olds with symptomatice non-erosive GERD Treating heartburn associated with non-erosive GERD in children N=100, protocol under review | Takeda Development Center Americas, Inc. | $116,839 | 0 |
| Safety and effectivness of TAK-390MR administered for 6 months to 1-11 yr olds with EE Healing, maintenance of healing & symptoms of endoscopy-proven EE in children N=60, protocol under review | Takeda Development Center Americas, Inc. | $100,383 | 0 |
| Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Effect of TAK-390MR 60 mg and Esomeprazole 40 mg on Bone Metabolism in Healthy Postmenopausal Female Subjects | Takeda Pharmaceuticals U.S.A., Inc. | $16,664 | 1 |
| Safety and effecxtiveness of TAK-390MR in 1-11yr olds with symptomatice non-erosive GERD Treating heartburn associated with non-erosive GERD in children N=100, protocol under review | Takeda Pharmaceuticals U.S.A., Inc. | $7,966 | 0 |
| A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Age 1 to 11 Months With Acid Related Diseases | Takeda Pharmaceuticals U.S.A., Inc. | $5,648 | 0 |
| Safety and effectivness of TAK-390MR administered for 6 months to 1-11 yr olds with EE Healing, maintenance of healing & symptoms of endoscopy-proven EE in children N=60, protocol under review | Takeda Pharmaceuticals U.S.A., Inc. | $4,260 | 0 |
| A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Age 1 to 11 Months With Acid Related Diseases | Takeda Development Center Americas, Inc. | $2,829 | 0 |
| Safety and effectiveness of TAK-390MR in 12-17 yr olds with symptomatice non-erosive GERD | Takeda Pharmaceuticals U.S.A., Inc. | $2,823 | 0 |
| Safety and effectiveness of TAK-390MR administered for 6 months to 12-17yr olds with EE | Takeda Pharmaceuticals U.S.A., Inc. | $610.82 | 0 |
Top Doctors Receiving Payments for Dexilant
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Fort Worth, TX | $257,396 | 92 |
| , M.D | Gastroenterology | Charlottesville, VA | $31,861 | 11 |
| , MD | Gastroenterology | Cleveland, OH | $21,210 | 10 |
| , M.D | Gastroenterology | Norfolk, VA | $5,009 | 2 |
| , M.D | Pediatrics | Mobile, AL | $1,975 | 3 |
| , MD | Pediatrics | Minneapolis, MN | $1,000 | 1 |
| , MD | Internal Medicine | Madison, WI | $641.62 | 2 |
| , MD | Gastroenterology | Brooklyn, NY | $584.14 | 36 |
| , M.D | Gastroenterology | Framingham, MA | $542.23 | 48 |
| , M.D | Gastroenterology | Tulsa, OK | $441.16 | 48 |
| , M.D., MSC | Gastroenterology | Smithtown, NY | $437.43 | 41 |
| Chaudry Ahmad Cheema | — | Rock Island, IL | $388.80 | 49 |
| , M.D | Gastroenterology | Amarillo, TX | $383.10 | 54 |
| , M.D | Gastroenterology | Amarillo, TX | $353.85 | 38 |
| , M.D | Gastroenterology | Charlotte, NC | $352.44 | 40 |
| , MD | Gastroenterology | Rutherford, NJ | $352.15 | 42 |
| , MD | Gastroenterology | Port St Lucie, FL | $332.00 | 29 |
| , M.D | Gastroenterology | Houston, TX | $324.01 | 25 |
| , MD | Specialist | Houston, TX | $323.63 | 19 |
| , MD | Gastroenterology | Cleveland, OH | $321.40 | 42 |
| Jin Suh | — | Los Angeles, CA | $316.58 | 35 |
| , MD | Gastroenterology | Louisville, KY | $316.39 | 34 |
| , MD | Internal Medicine | San Mateo, CA | $315.76 | 26 |
| , MD | Internal Medicine | New York, NY | $302.02 | 10 |
| , MD | Gastroenterology | Honolulu, HI | $301.95 | 16 |
Ad
Manufacturing Companies
- Takeda Development Center Americas, Inc. $220,051
- Takeda Pharmaceuticals U.S.A., Inc. $170,662
- Takeda Pharmaceuticals America, Inc. $116,724
- Takeda Pharmaceuticals International, Inc. $31,868
- Hikma Pharmaceuticals USA $26,203
- Takeda Pharmaceuticals Puerto Rico LLC $361.77
Product Information
- Type Drug
- Total Payments $565,871
- Total Doctors 7,557
- Transactions 22,379
About Dexilant
Dexilant is a drug associated with $565,871 in payments to 7,557 healthcare providers, recorded across 22,379 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Development Center Americas, Inc..
Payment data is available from 2017 to 2024. In 2024, $21,203 was paid across 9 transactions to 1 doctors.
The most common payment nature for Dexilant is "Unspecified" ($258,023, 45.6% of total).
Dexilant is associated with 9 research studies, including "Safety and effecxtiveness of TAK-390MR in 1-11yr olds with symptomatice non-erosive GERD Treating heartburn associated with non-erosive GERD in children N=100, protocol under review" ($116,839).